Despite being well characterized in AD, therapeutics targeting amyloid or tau pathologies have had limited success in human clinical trials61–63 so understanding how peripheral factors, such as the gut microbiota, contribute to pathology development is critical. The gene discussed is MAPT; the disease is Alzheimer disease.